{"brief_title": "The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes", "brief_summary": "The purpose of this study are to determine 1) Whether Ly333531 can reduce urinary albumin/creatinine excretion in patients with Type II diabetes and persistent albuminuria 2) Whether LY333531 reduces urinary TGF-B, 3) the safety of LY333531 and any side effects that may be associated with it.", "condition": "Diabetic Nephropathy", "intervention_type": "Drug", "intervention_name": "LY333531", "criteria": "Inclusion Criteria: - Type 2 diabetes mellitus - Greater than or equal to 30 years of age - Albumin to Creatinine ratio (greater than 200 mg/g and less than 2000 mg/g) 4)Without language barrier. Exclusion Criteria: - Serum Creatinine greater than 2.0 mg/dl males or greater than 1.7 mg/dl females - B/P greater than 150 systolic and greater than 90 diastolic - Hemoglobin Alc greater than 11% - Liver Function Tests 2 times upper limit of normal - Poor medical or psychiatric risk.", "gender": "All", "minimum_age": "30 Years", "maximum_age": "N/A", "healthy_volunteers": "Accepts Healthy Volunteers", "id": "NCT00044148.xml"}